Biotech President welcomes the position of the SPD's Economic Forum – economic experts emphasize the importance of biotechnology
(Berlin – January 17, 2024) In a position paper published today, the SPD's Economic Forum states that biotechnology is one of the major drivers of innovation and a key industry and technology for Germany as a business location. It offers a wide range of applications, including the development of personalized medicines and regenerative therapies, as well as the breeding of plant species that are more resistant to pests and environmental influences, which in turn improves food security and sustainability. Seven demands are intended to help strengthen the German biotech location. The biotechnology industry association BIO Deutschland welcomes this clear commitment to the potential of biotechnology in all fields of application and the demands of the forum.
Oliver Schacht, Chairman of the Board of BIO Deutschland, explains: “It is important for our innovative industry that the SPD Economic Forum has taken a close look at biotechnology as a key technology in all relevant fields of application. The outcome of the hearing process with proven experts has shown that the potential of biotechnology is very high, and not only in medicine, but also in plant breeding and environmental and climate protection. The demands of the forum to strengthen biotechnology in this country are in line with our call for a biotechnology agenda for Germany.”
About BIO Deutschland:
BIO Deutschland e. V., based in Berlin, has around 380 members – companies, BioRegions and industry service providers – and aims to support and promote the development of an innovative industry in Germany based on modern life sciences. Oliver Schacht, Ph. D., is Chairman of the Board of BIO Deutschland.
Further information is available at: www.biodeutschland.org
BIO Deutschland's supporting members and industry partners are:
AGC Biologics, Avia, Baker Tilly, Bayer, BioSpring, Boehringer Ingelheim, Centogene, Citeline, CMS Hasche Sigle, Deutsche Bank, Ernst & Young, Evotec, KPMG, Lonza, Miltenyi Biotec, MorphoSys , Novartis, Pfizer, PricewaterhouseCoopers, QIAGEN, Rentschler Biopharma, Roche Diagnostics, Sanofi Aventis Deutschland, Schmidt Versicherungs Treuhand, Simmons & Simmons, Springer Nature, Thermo Fisher Scientific, Vertex Pharmaceuticals, Vibalogics, ZETA.
Contact:
BIO Deutschland e. V.
Dr. Claudia Englbrecht
Schützenstraße 6a
10117 Berlin
Tel.: +49 30 2332 164-32
Mobile: +49 151 14067326
E-Mail: englbrecht@biodeutschland.org